Why study with a clinical analysis, has come to use exactly the opposite conclusion? In fact, medical research that involves the observation point, if selected to observe the different indicators, it may not arrive at consistent results. Simply an application for biomedical research are often not black and white clear conclusions, which may be difficult to non-professionals to understand. However, the study of Japan, it is certain that through this study, but also can not deny the aspirin in the prevention of diabetes in patients with cardiovascular and cerebrovascular risk in an active role.
Aspirin is recommended for the prevention of cardiovascular and cerebrovascular disease, according to the world so far has been the participation of hundreds of thousands of people more than 200 randomized clinical study confirmed that aspirin can effectively prevent and treat cardiovascular and cerebrovascular events. In addition, its low cost, aspirin was cardio-cerebral-vascular community as the "prevention and treatment of cardiovascular and cerebrovascular events cornerstone" is also the world's most prescribed cardiovascular and cerebrovascular disease prevention and treatment drug.
In the field of diabetes, the first devoted to the study in 1992 patients with diabetes to participate in 3771 in the early treatment diabetic retinopathy study showed that aspirin in patients with diabetes the risk of death and myocardial infarction significantly reduced. More well-known is the 1989 U.S. physicians health study of 22,071 initially healthy U.S. male physicians healthy 5-year follow-up oral aspirin, aspirin was found in diabetic patients significantly reduced the risk of myocardial infarction. Published in 2005 a total of women's health study of 39,876 initially healthy American women to participate in medical, oral aspirin follow-up time of up to 10 years, the results show that aspirin can also occur in diabetic patients the risk of cerebral infarction has declined markedly.
This year, New Orleans in the United States organized by the American Heart Association meeting in 2008, a new study released by J-PAD results suggest that low-dose aspirin may significantly reduce death in patients with type 2 diabetes and cardio-cerebral vascular disease risk. The study is the first in Asia to focus on diabetes research aspirin groups, 163 of the Medical Center of Japan 2539 the 30-year-old to 85-year-old patients with type 2 diabetes for an average of 4.37 years of follow-up dose aspirin use 81 mg daily or 100 mg. The results showed that aspirin significantly reduced the first time in patients with type 2 diabetes and coronary heart disease and stroke death risk in patients over the age of 65 was more significant benefits.
Safety results showed that long-term treatment with aspirin did not significantly increase the risk of bleeding, after the Asian population, many experts worried that the use of anti-platelet drug more susceptible to bleeding, but the J-PAD study showed that low-dose aspirin in diabetic populations in Asia the same with good security.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment